Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

The Lancet Oncology - Tập 23 - Trang 650-658 - 2022
Syed A Hussain1, Jason F Lester2, Richard Jackson3, Matthew Gornall3, Muneeb Qureshi1, Anthony Elliott4, Simon J Crabb5, Robert A Huddart6, Naveen Vasudev7, Alison J Birtle8, Jane Worlding9, Nicholas D James6, Omi Parikh8, Maria Vilarino-Varela10, Roberto Alonzi11, Mark D Linch12, Irbaz B Riaz13, James W F Catto14, Thomas Powles15, Robert J Jones16
1Department of Oncology and Metabolism, Academic Unit of Oncology, University of Sheffield, Sheffield, UK
2Velindre Cancer Centre, Cardiff, UK
3Department of Oncology, University of Liverpool, Liverpool, UK
4Christie Hospital, Manchester, UK
5Department of Oncology, University of Southampton, Southampton, UK
6Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK
7St James's University Hospital, Leeds, UK
8Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK
9University Hospital Coventry, Coventry, UK
10Royal Free Hospital, London, UK
11Mount Vernon Cancer Centre, Northwood, UK
12University College London Cancer Institute, London, UK
13Mayo Clinic, Phoenix, AZ, USA
14Academic Urology Unit, University of Sheffield, Sheffield, UK
15Barts Cancer Institute, Queen Mary University London, London, UK
16University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 23

650-658

Thông tin tác giả